Anti-Pseudomonas aeruginosa PcrV & Psl Bispecific Reference Antibody (Gremubamab, RUO) (JN076016)

Name: Anti-Pseudomonas aeruginosa PcrV & Psl Bispecific Reference Antibody (Gremubamab, RUO)
Brand: abinScience
SKU: JN076016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	JN076016
Description	Gremubamab (JN076016) is a research-grade recombinant antibody targeting PcrV & Psl. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Pseudomonas aeruginosa
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	VH-CH1-VH-V-KAPPA-CH2-CH3
Système d'expression	Mammalian cells
Cible	PcrV & Psl
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	O30527
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	Bispecific, MEDI3902, CAS: 1800381-36-5
Contexte	Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections. • A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis., PMID:38754132 • Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates., PMID:30016475 • Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide., PMID:26333940 • Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults., PMID:30107283 • AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia., PMID:38678160 • Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature., PMID:28463232 • Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models., PMID:31160288 • Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets., PMID:30185667 • Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice., PMID:33147726 • Antivirulence Bispecific Monoclonal Antibody-Mediated Protection against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model., PMID:34902264
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects PcrV in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Gremubamab

Reférences

Fiche technique

Anti-Pseudomonas aeruginosa PcrV & Psl Bispecific Reference Antibody (Gremubamab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Protéines Recombinantes

Anticorps

Kits d'Essai